{"id":2969,"date":"2018-04-26T05:00:00","date_gmt":"2018-04-26T05:00:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/xvivo-perfusion-ab-publ-delarsrapport-januari-mars-2018\/"},"modified":"2018-04-26T05:00:00","modified_gmt":"2018-04-26T05:00:00","slug":"xvivo-perfusion-ab-publ-delarsrapport-januari-mars-2018","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-delarsrapport-januari-mars-2018\/","title":{"rendered":"XVIVO Perfusion AB (publ) del\u00e5rsrapport januari \u2013 mars 2018"},"content":{"rendered":"
REKORDF\u00d6RS\u00c4LJNING UNDER KVARTALET OCH GOD EBITDA<\/strong><\/div>\n

F\u00d6RSTA KVARTALET 2018 (JAN \u2013 MAR)<\/p>\n

\u2022 Segment f\u00f6rs\u00e4ljning utan kapitalvaror \u00f6kade under kvartalet med 13 procent och uppgick till 37,9 MSEK (33,6). \u00d6kningen motsvarar 17 procent i lokala valutor. Den totala f\u00f6rs\u00e4ljningen under kvartalet \u00f6kade med 13 procent och uppgick till 42,5 MSEK (37,5). \u00d6kningen motsvarar 18 procent i lokala valutor.
\u2022 R\u00f6relseresultatet f\u00f6re avskrivningar (EBITDA) uppgick till 7,2 MSEK motsvarande en EBITDA-marginal om 17 procent. F\u00f6r j\u00e4mf\u00f6relsekvartalet 2017 uppgick EBITDA justerat f\u00f6r j\u00e4mf\u00f6relsest\u00f6rande poster till 5,0 MSEK motsvarande en EBITDA marginal om 13 procent.
\u2022 R\u00f6relseresultatet uppgick till 3,1 MSEK (0,0), efter avskrivningar om 4,0 MSEK (3,7).
\u2022 Nettoresultatet uppgick till 3,8 MSEK (0,0), vilket gav ett resultat per aktie om 0,15 SEK (0,00).
\u2022 Kassafl\u00f6det fr\u00e5n den l\u00f6pande verksamheten var 9,2 MSEK (-2,0).
\u2022 F\u00f6rs\u00e4ljning av varm perfusion (STEEN Solution\u2122 samt produkter och tj\u00e4nster relaterade till anv\u00e4ndningen av XPS\u2122 och LS\u2122) stod f\u00f6r 35 procent (36) av f\u00f6rs\u00e4ljningen utan kapitalvaror.
\u2022 Reimbursement-koder (s.k. CPT-koder) f\u00f6r hela EVLP-processen i USA har varit p\u00e5 plats sedan 1 januari 2018, vilket f\u00f6renklar ers\u00e4ttningsprocessen f\u00f6r sjukhus p\u00e5 den amerikanska marknaden.
\u2022 2 XPS\u2122 levererades under kvartalet. Vid kvartalets utg\u00e5ng hade 47 kliniker tillg\u00e5ng till XPS\u2122 eller LS\u2122.<\/p>\n

TELEFONKONFERENS<\/p>\n

VD Magnus Nilsson presenterar rapporten vid en telefonkonferens klockan 14:00 torsdagen den 26 april 2018. Telefon: +46 (0)8 5059 6306, ange kod 17299565#<\/p>\n

G\u00f6teborg den 26 april 2018
XVIVO Perfusion AB (publ)
Magnus Nilsson, VD<\/p>\n

\n

F\u00f6r ytterligare information, v\u00e4nligen kontakta: <\/span><\/p>\n

Christoffer Rosenblad, CFO, +46 735 192159, christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, VD, +46 31-788 21 50, magnus.nilsson@xvivoperfusion.com<\/span><\/p>\n

F\u00f6r ytterligare information om XVIVO Perfusions verksamhet h\u00e4nvisas till bolagets hemsida, www.xvivoperfusion.com<\/span><\/p>\n

Denna information \u00e4r s\u00e5dan information som Xvivo Perfusion AB (publ) \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersons f\u00f6rsorg, f\u00f6r offentligg\u00f6rande klockan 7:00 den 26 april 2018.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

REKORDF\u00d6RS\u00c4LJNING UNDER KVARTALET OCH GOD EBITDA F\u00d6RSTA KVARTALET 2018 (JAN \u2013 MAR) \u2022 Segment f\u00f6rs\u00e4ljning utan kapitalvaror \u00f6kade under kvartalet…<\/p>\n","protected":false},"template":"","class_list":["post-2969","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-mar","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-report-interim-q1"],"acf":[],"yoast_head":"\nXVIVO Perfusion AB (publ) del\u00e5rsrapport januari \u2013 mars 2018 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-delarsrapport-januari-mars-2018\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XVIVO Perfusion AB (publ) del\u00e5rsrapport januari \u2013 mars 2018 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"REKORDF\u00d6RS\u00c4LJNING UNDER KVARTALET OCH GOD EBITDA F\u00d6RSTA KVARTALET 2018 (JAN \u2013 MAR) \u2022 Segment f\u00f6rs\u00e4ljning utan kapitalvaror \u00f6kade under kvartalet...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-delarsrapport-januari-mars-2018\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-delarsrapport-januari-mars-2018\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-delarsrapport-januari-mars-2018\\\/\",\"name\":\"XVIVO Perfusion AB (publ) del\u00e5rsrapport januari \u2013 mars 2018 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2018-04-26T05:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-delarsrapport-januari-mars-2018\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-delarsrapport-januari-mars-2018\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-delarsrapport-januari-mars-2018\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XVIVO Perfusion AB (publ) del\u00e5rsrapport januari \u2013 mars 2018\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XVIVO Perfusion AB (publ) del\u00e5rsrapport januari \u2013 mars 2018 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-delarsrapport-januari-mars-2018\/","og_locale":"en_US","og_type":"article","og_title":"XVIVO Perfusion AB (publ) del\u00e5rsrapport januari \u2013 mars 2018 - XVIVO","og_description":"REKORDF\u00d6RS\u00c4LJNING UNDER KVARTALET OCH GOD EBITDA F\u00d6RSTA KVARTALET 2018 (JAN \u2013 MAR) \u2022 Segment f\u00f6rs\u00e4ljning utan kapitalvaror \u00f6kade under kvartalet...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-delarsrapport-januari-mars-2018\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-delarsrapport-januari-mars-2018\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-delarsrapport-januari-mars-2018\/","name":"XVIVO Perfusion AB (publ) del\u00e5rsrapport januari \u2013 mars 2018 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2018-04-26T05:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-delarsrapport-januari-mars-2018\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-delarsrapport-januari-mars-2018\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-delarsrapport-januari-mars-2018\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"XVIVO Perfusion AB (publ) del\u00e5rsrapport januari \u2013 mars 2018"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/2969","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=2969"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}